A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2
Clinical trial NCT05113862 · COMPLETED
Trial details
- NCT number
- NCT05113862
- Sponsor
- Gylden Pharma Ltd
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-10
- Primary completion
- 2022-09-15
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.